Positive high-level results from the MATTERHORN Phase III trial showed perioperative treatment with AstraZeneca’s (AZN) Imfinzi in combination ...

Results from the MATTERHORN Phase III trial showed perioperative treatment with AstraZeneca’s (AZN) Imfinzi in combination with ...

Imfinzi is one of AstraZeneca’s key growth drivers for 2025, with potential approvals in stomach and bladder cancers. The ...

AstraZeneca is preparing to talk to the FDA about a potential new use of its immunotherapy Imfinzi after a pivotal study in ...

Preliminary trial results demonstrated that Imfinzi plus chemo improved event-free survival in resectable early-stage gastric ...

AstraZeneca Plc (NASDAQ:AZN) released high-level results from the MATTERHORN Phase 3 trial evaluating Imfinzi (durvalumab) as ...

AstraZeneca (AZ) has shared positive results from a late-stage trial of its Imfinzi (durvalumab)-based perioperative regimen ...

"Matterhorn is the first phase III trial of an immunotherapy to show a statistically significant improvement in event-free survival in patients with resectable gastric and gastroesophageal junction ...

A treatment combining AstraZeneca’s (LSE: AZN) immunotherapy Imfinzi (durvalumab) with chemotherapy has significantly reduced ...

AstraZeneca said its Imfinzi drug when used with chemotherapy had shown “statistically significant and clinically meaningful improvement” in survival in resectable early-stage gastric and ...

Topline results were announced from a phase 3 trial evaluating durvalumab in combination with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) ...

ScaleUps Ventures, a leading UK-based Health and Social Care startup accelerator announced its 2025 cohort of 11 pioneering companies to deliver on the innovation needs of the NHS and private sector.